|

Vorasidenib Clinical Trials

4 actively recruiting trials across 1 location

▲ +1 trial since June 2026

Also known as: AG-881, S095032

Pipeline

Phase 3: 2

Top Sponsors

  • iOMEDICO AG1
  • Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta1
  • European Organisation for Research and Treatment of Cancer - EORTC1
  • Alliance for Clinical Trials in Oncology1

Indications

  • Cancer4
  • Glioma2
  • Low Grade Gliomas1
  • IDH-mutant Grade 2 or 3 Astrocytoma1
  • Low Grade Glioma of Brain1

Other3 trials

Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared
Vorasidenib Maintenance for IDH Mutant Astrocytoma
Phase 3
Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma

Duarte, California1 trial

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

City of Hope Comprehensive Cancer Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.